Plain-English translation of NCT06344156 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of three treatments given after pancreatic cancer surgery: chemotherapy (gemcitabine and capecitabine), an immune-boosting drug called tislelizumab, and a personalized neoantigen vaccine. The neoantigen vaccine is custom-made from your own tumor to help your immune system recognize and fight any remaining cancer cells. Researchers want to see if this combination can help keep the cancer from coming back.
Pancreatic cancer often returns even after successful surgery, so doctors are looking for better ways to prevent recurrence. This medication and vaccine combination takes a new approach by training your immune system to target cancer cells that may be hiding in your body after surgery.
You likely qualify if…
You likely don't qualify if…
You would receive the treatment in three parts over about 4 months: chemotherapy pills and intravenous infusions every 3 weeks for 8 cycles, the immune-boosting medication given by IV infusion, and the personalized vaccine given by IV infusion at specific timepoints (starting doses, then booster doses later). You would visit the hospital regularly for infusions and blood tests to monitor how well the treatment is working and watch for side effects. The trial is conducted at a single center in China and requires your commitment to complete the full treatment schedule and follow-up visits.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China